TABLE 3.

Summary of Treatment-Emergent Adverse Events (Safety Analysis Set).

Participants With AE	RE104 5 mg (N=6) n (%) E	RE104 10 mg (N=6) n (%) E	RE104 20 mg (N=6) n (%) E	RE104 30 mg (N=9) n (%) E	RE104 35 mg (N=6) n (%) E	RE104 40 mg (N=3) n (%) E	Pooled Placebo (N=12) n (%) E
≥1 TEAE	2 (33.3) 3	2 (33.3) 4	2 (33.3) 5	8 (88.9) 30	5 (83.3) 31	3 (100) 16	4 (33.3) 5
Nausea	1 (16.7) 1	2 (33.3) 2	0	3 (33.3) 3	2 (33.3) 2	2 (66.7) 2	0
Sinus tachycardia	0	0	0	4 (44.4) 8	3 (50.0) 7	2 (66.7) 4	0
Restlessness	0	0	0	3 (33.3) 3	3 (50.0) 3	1 (33.3) 1	0
Headache	0	1 (16.7) 1	0	1 (11.1) 2	4 (66.7) 4	0	0
Agitation	0	0	0	0	2 (33.3) 3	2 (66.7) 3	0
Muscle twitching	0	0	0	3 (33.3) 4	0	0	0
Diarrhea	0	0	1 (16.7) 1	0	2 (33.3) 2	0	0
Hyperhidrosis	0	0	1 (16.7) 1	0	1 (16.7) 1	1 (33.3) 1	0
Abdominal pain	0	0	0	2 (22.2) 2	0	0	0
Vomiting	1 (16.7) 1	0	0	0	0	1 (33.3) 1	0
Fatigue	0	0	0	2 (22.2) 2	0	0	0
Thirst	0	0	0	0	2 (33.3) 2	0	0
Tremor	0	0	0	1 (11.1) 1	0	1 (33.3) 1	0
Feeling hot	0	0	1 (16.7) 1	0	0	0	1 (8.3) 1
Myalgia	0	0	0	0	1 (16.7) 2	0	0
Dysphoria	0	0	0	0	1 (16.7) 2	0	0
Gastroenteritis	0	0	0	0	0	0	1 (8.3) 1
Chest discomfort	0	1 (16.7) 1	0	0	0	0	0
Injection site bruising	0	0	0	1 (11.1) 1	0	0	0
Folliculitis	1 (16.7) 1	0	0	0	0	0	0
Musculoskeletal injury	0	0	0	1 (11.1) 1	0	0	1 (8.3) 2
Palpitations	0	0	1 (16.7) 1	0	0	0	1 (8.3) 1
Ageusia	0	0	0	0	1 (16.7) 1	0	0
Syncope	0	0	0	1 (11.1) 1	0	0	0
Tension headache	0	0	0	1 (11.1) 1	0	0	0
Anxiety	0	0	1 (16.7) 1	0	0	0	0
Fear	0	0	0	0	0	1 (33.3) 1	0
Hallucination	0	0	0	0	1 (16.7) 1	0	0
Irritability	0	0	0	0	0	1 (33.3) 1	0
Hypotension	0	0	0	0	1 (16.7) 1	0	0